drug · small molecule
fenebrutinib
Phase 3updated 6mo agoby Genentech Inc🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 8 investigational indications.
targets
Tyrosine-protein kinase BTK
all catalysts(0)
nothing on the calendar yet
Trials studying fenebrutinib
- phase2A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
- phase3A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
- phase3A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
- phase3Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
- phase2A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)
News(7)
- STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trialsAn MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment.stat · 24d ago
- Roche builds blockbuster BTK case for fenebrutinib in multiple sclerosis as FDA decision approachesRoche has dived into the data behind its filing for FDA approval of fenebrutinib in multiple sclerosis, unpacking the BTK inhibitor’s effect on chronic active lesions, disease control and brain vol…fiercebiotech · 27d ago
- FDA starts review of Roche’s multiple sclerosis pillThe FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety questions still hang over Roche’s program.biopharma_dive · 1mo ago
- ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the futureWhen recombinant DNA pioneer Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time.fiercebiotech · 1mo ago
- Roche, Ionis RNA drug scores in kidney disease studyThe results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.biopharma_dive · 1mo ago
- Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battleNovartis is planning to file for remibrutinib’s expanded approval in relapsing multiple sclerosis by next year, putting it just behind Roche's own BTK inhibitor fenebrutinib.biospace · 2mo ago
- Merck adds to pharma’s AI push; Roche details MS drug resultsMerck is making a $1 billion investment in a deal with Google Cloud. Elsewhere, Roche pitched its case for a closely watched multiple sclerosis pill and Arcus and Gilead are ending a yearslong alli…biopharma_dive · 6mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that